Loading
A phase 3 trial of Relugolix in endometrial cancer, run by Sumitomo Pharma Switzerland GmbH, now recruiting.
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis is a phase 3 interventional study registered as NCT05862272 by Sumitomo Pharma Switzerland GmbH, with 1000 participants planned, started 2023-08-14 and due to reach its primary completion in 2029-07. Interventions recorded: Relugolix Combination Tablet.
Shares Sumitomo Pharma (Myovant) and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors and the tag pipeline.
Shares Relugolix and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors and the tag pipeline.
Shares Sumitomo Pharma (Myovant) and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors and the tag pipeline.